cardiac glycosides	are	drugs
cardiac glycosides	treat	heart failure
cardiac glycosides	treat	atrial fibrillation
cardiac glycosides	increase	cardiac contractility
cardiac glycosides	inhibit	Na⁺/K⁺‑ATPase
Na⁺/K⁺‑ATPase	regulates	intracellular Na⁺
intracellular Na⁺	affects	Ca²⁺ influx
Ca²⁺ influx	enhances	myocardial force
cardiac glycosides	derived from	foxglove
foxglove	contains	digitoxin
digitoxin	is a	cardiac glycoside
cardiac glycosides	include	digoxin
digoxin	used for	ventricular arrhythmia
digoxin	has	narrow therapeutic index
narrow therapeutic index	leads to	toxicity risk
digoxin toxicity	causes	nausea
digoxin toxicity	causes	vomiting
digoxin toxicity	causes	visual changes
visual changes	include	yellow‑green halos
digoxin toxicity	causes	arrhythmia
arrhythmia	can be	ventricular tachycardia
cardiac glycosides	contraindicated in	hyperkalemia
hyperkalemia	increases	arrhythmia risk
cardiac glycosides	contraindicated in	renal failure
renal failure	reduces	drug clearance
cardiac glycosides	contraindicated in	hepatic failure
hepatic failure	reduces	metabolism
cardiac glycosides	interact with	amiodarone
amiodarone	increases	digoxin levels
cardiac glycosides	interact with	verapamil
verapamil	increases	digoxin levels
cardiac glycosides	interact with	quinidine
quinidine	increases	digoxin levels
cardiac glycosides	interact with	cimetidine
cimetidine	increases	digoxin levels
cardiac glycosides	interact with	beta‑blockers
beta‑blockers	mask	digoxin toxicity
cardiac glycosides	monitored by	serum digoxin level
serum digoxin level	measured in	blood
blood	sampled via	venipuncture
cardiac glycosides	dosage adjusted by	renal function
renal function	assessed by	eGFR
eGFR	calculated from	creatinine
creatinine	measured in	serum
cardiac glycosides	dosage adjusted by	age
age	influences	drug metabolism
cardiac glycosides	dosage adjusted by	weight
weight	influences	volume of distribution
cardiac glycosides	used in	chronic heart failure
chronic heart failure	predicts	mortality
cardiac glycosides	improve	ejection fraction
ejection fraction	predicts	survival
cardiac glycosides	reduce	hospital readmission
hospital readmission	predicts	healthcare cost
cardiac glycosides	reduce	mortality
mortality	predicted by	NYHA class
NYHA class	graded by	functional capacity
functional capacity	measured by	6‑minute walk
6‑minute walk	predicts	prognosis
cardiac glycosides	associated with	bradycardia
bradycardia	leads to	syncope
syncope	increases	fall risk
fall risk	predicts	injury
injury	leads to	hospitalization
hospitalization	increases	readmission risk
cardiac glycosides	used with	ACE inhibitors
ACE inhibitors	reduce	afterload
afterload	reduces	cardiac workload
cardiac workload	reduces	ischemia
ischemia	predicts	arrhythmia
arrhythmia	treated by	antiarrhythmic drugs
antiarrhythmic drugs	include	amiodarone
amiodarone	interacts with	digoxin
digoxin	metabolized by	CYP3A4
CYP3A4	inhibited by	ketoconazole
ketoconazole	increases	digoxin levels
digoxin	excreted by	kidneys
kidneys	function assessed by	creatinine clearance
creatinine clearance	predicts	drug clearance
drug clearance	influences	dosing interval
dosing interval	affects	trough level
trough level	predicts	toxicity
toxicity	leads to	mortality
mortality	predicted by	serum digoxin level
serum digoxin level	monitored by	immunoassay
immunoassay	detects	digoxin concentration
digoxin concentration	expressed as	ng/mL
ng/mL	used to	guide therapy
therapy	guided by	clinical guidelines
clinical guidelines	recommend	target range
target range	set at	0.5‑2.0 ng/mL
cardiac glycosides	contraindicated in	pregnancy
pregnancy	increases	fetal risk
fetal risk	includes	teratogenicity
teratogenicity	leads to	congenital defects
congenital defects	increase	neonatal morbidity
neonatal morbidity	predicts	long‑term outcomes
long‑term outcomes	influenced by	early intervention
early intervention	improves	survival
survival	measured by	5‑year mortality
